Who staffs an antimicrobial stewardship program?

Guidelines describe a multidisciplinary team, typically led by an infectious-diseases physician and a clinical pharmacist with infectious-diseases training, supported by institutional leadership and working with microbiology, infection prevention, and information technology.

How are stewardship programs evaluated?

Programs are judged by process metrics such as antimicrobial consumption (for example, days of therapy) and by outcome metrics such as guideline-concordant prescribing, resistance rates, Clostridioides difficile infection, and cost, ideally alongside measures confirming no patient harm.

Stewardship Program Implementation and Outcomes

An antimicrobial stewardship program is the institutional structure - a multidisciplinary team, leadership support, and a defined set of interventions and metrics - through which the principles of stewardship are put into practice. This topic covers how such programs are built and staffed, the interventions they deploy, the behavioural and organisational factors that determine their success, and the outcomes used to judge them.

Definition

Stewardship program implementation and outcomes concern the establishment and operation of an institutional antimicrobial stewardship program - its multidisciplinary team, leadership support, interventions, and metrics - and the assessment of its effects on prescribing, resistance, infection-related harms, and resource use.

Scope

This topic covers the implementation of stewardship programs (team composition, leadership commitment, core and supplemental interventions) and the outcomes by which they are evaluated, including prescribing, resistance, Clostridioides difficile rates, and cost. It is an organisational and evidence-appraisal topic about program-level practice and does not provide individual prescribing guidance.

Core questions

What structures and personnel make up an effective stewardship program?
Which interventions do programs use, and how are they chosen?
What outcomes are used to evaluate stewardship, and what does the evidence show?
Why do behavioural and organisational factors shape program success?

Key concepts

Multidisciplinary stewardship team
Leadership commitment and accountability
Prospective audit and feedback
Preauthorization
Process and outcome metrics (days of therapy, resistance rates)
Behaviour change and prescribing culture
Clostridioides difficile and cost outcomes

Mechanisms

A stewardship program operationalises stewardship principles by assembling a team - typically including an infectious-diseases physician and a clinical pharmacist with infectious-diseases training - backed by institutional leadership and accountable for a defined set of interventions. These interventions, chiefly prospective audit with feedback and preauthorization, are selected to fit local resources and prescribing patterns. Because prescribing is a social and behavioural act embedded in institutional culture, the effectiveness of these interventions depends on how they engage prescribers, which is why behaviour-change theory has been brought to bear on program design. Programs measure their effect through process metrics (such as antimicrobial consumption expressed as days of therapy) and outcome metrics (such as resistance rates, Clostridioides difficile infection, and cost).

Clinical relevance

Understanding how stewardship programs are structured and evaluated supports critical appraisal of stewardship outcome studies and infection-prevention literature. Systematic reviews and a meta-analysis report that well-implemented programs increase guideline-concordant prescribing and can reduce antimicrobial consumption, resistant infections, and Clostridioides difficile rates, generally without evidence of patient harm. This entry describes program-level evidence and is not a basis for individual diagnostic or treatment decisions.

Epidemiology

Stewardship programs have become an expected feature of hospitals in many health systems, increasingly tied to accreditation and regulatory requirements, and their outcomes are tracked through standardised antimicrobial-use and resistance surveillance metrics at institutional and national levels.

Evidence & guidelines

The 2007 and 2016 IDSA/SHEA guidelines define program structure and interventions. The Cochrane review (Davey et al., 2017) and the meta-analysis by Schuts and colleagues (2016) summarise outcomes; Tamma and colleagues (2016) compare preauthorization with audit-and-feedback; and Charani and colleagues (2011) review behaviour-change strategies underpinning program design.

History

The institutional stewardship program as a defined entity emerged from the 2007 IDSA/SHEA guideline, which set out team composition and the core interventions. Through the 2010s, accumulating outcome evidence, the incorporation of behaviour-change science, and regulatory and accreditation mandates moved such programs from optional initiatives toward standard institutional infrastructure, a shift reflected in the expanded 2016 implementation guideline.

Debates

Preauthorization versus prospective audit and feedback: Both core interventions can improve prescribing, but they differ in speed, durability, staffing demands, and effect on prescriber relationships; comparative studies inform but do not fully settle which to prioritise in a given setting.
How much do behavioural and cultural factors determine success?: Because prescribing is a social act, reviews argue that program effectiveness depends heavily on engaging prescriber behaviour and culture rather than on intervention type alone, though the best way to do so is still debated.

Seminal works

dellit-2007
barlam-2016
davey-2017

Frequently asked questions

Who staffs an antimicrobial stewardship program?: Guidelines describe a multidisciplinary team, typically led by an infectious-diseases physician and a clinical pharmacist with infectious-diseases training, supported by institutional leadership and working with microbiology, infection prevention, and information technology.
How are stewardship programs evaluated?: Programs are judged by process metrics such as antimicrobial consumption (for example, days of therapy) and by outcome metrics such as guideline-concordant prescribing, resistance rates, Clostridioides difficile infection, and cost, ideally alongside measures confirming no patient harm.